Lerner, M., Annals of the New York Academy of Sciences, vol. 885, pp. 153-160. |
Schioth, et al., Neuropeptides, vol. 33, No. 3, pp. 191-196, 1999. |
Bednarek, et al., “Analogs of MTII, Lactam Derivatives of a-Melanotropin, Modified at the N-Terminus and their Selectivity at Human Melanocortin Receptors 3,4 and 5” Biochem. Bioph. Res. Com. 1999, 261, 209-213. |
Sawyer, et al., “4-Norleucine, 7-D-Phenylalanine-a-Melanocyte-Stimulating Hormone: A Highly Potent a-Melanotropin with Ultralong Biological Activity” Proc. Natl. Acad. Sci. USA 1980, 77, 5754-5758. |
Kask, et al., “Evidence of involvement of the Melanocortin MC4 Receptor in the Effects of Leptin on Food Intake & Body Weight”, Eur. J. Pharmacology 1998, 360, 15-19. |
Fan, et al. “Role of Melanocortinergic Neurons in Feeding and the Agouti Obesity Syndrome” Nature 1997, 385, 165-168. |
Schioth, et al., “Major Pharacological Distinction of the ACTH Receptor from Other Melanocortin Receptors” Life Sci. 1996, 59, 797-801. |
Griffon, et al., “Molecular Cloning, Expression and Characterization of a Fifth Melanocortin Receptor”, Biochem. Biophys. Res. Commun. 1994, 200, 1007-1014. |
Wessells, et al. “Synthetic Melanotropic Peptide Initiates Erections in Man with Psychogenic Erectile Dysfunction: Double-Blind, Placebo Controlled Crossover Study”, J Urology 1998, 160, 389-393. |
Wikberg, “Melanocortin Receptors: Perspective for Novel Drugs”, Eur. J. Pharmacology 1999, 375, 295-310. |
Chen, et al., “exocrine Gland Dysfunction in MC5-R Deficient Mice: Evidence for Coordinated Regulation of Exocrine Function in Melanocortin Peptides”, Cell 1997, 91, 789-798. |
Kask, et al., “Evidence that Orexigenic Effects of Melanocortin 4 Receptor Antagonist HS014 are Mediated by Neuropeptide”, Y. Biochem, Bioph. Res. Commun, 1998, 248, 245-249. |
Kask, et al., “Selective Antagonist for the Melanocortin 4 Receptor (HS014) Increases Food Intake in Free-Feeding Rats”, Biochem. Bioph. Res. Commun. 1998, 245, 90-93. |
Murphy, et al., “Melanocortin Mediated Inhibition of Feeding Behavior in Rats” Neuropeptides 1998, 32, 491-497. |
Giraudo, et al., “Feeding Effects of Hypothalamic Injection of Melanocortin 4 Receptor Ligands” Brain Res. 1998, 809, 302-306. |
Huszar, et al. “Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice” Cell 1997, 88, 131-141. |
Hruby, et al., Cyclic Lactam a-Melanotropin Analogues of Ac-4-cyclo[Asp5,D-Phe7,Lys10]a Melanocyte-Stimulating Hormone-(4-10)-NH2 with Bulky Aromatic Amino Acids at Position 7 Show Ant. Potency and Selectivity at Specific Malanocortin Receptors J. Med. Chem., 1995, 38, 3454-3461. |
Kask, et al., “Discovery of a Novel Superpotent and Selective Melanocortin-4 Receptor Antagonist (HS024): Evaluation in Vitro and in Vivo” Endocrinology, 1998, 139, 5006-5014. |
Skuladottir, et al., “Long Term Orexigenic Effect of a Novel Melanocortin 4 Receptor Selective Antagonist” Brit. J. Pharmacology, 1999, 126, 27-34. |
Bednarek, et al., “Structure-Function Studies on the Cyclic PeptideMT-II, Lactam Derivative of a-Melanotropin” Peptides 1999, 20, 401-409. |
Haskell-Luevano, et al., “Discovery of Prototype Peptidomimetic Agonists at the Human Melanocortin Receptors MC1R and MC4R” J. Med. Chem., 1997, 40, 2133-2139. |
Schioth, et al., “Selective Properties of C- and N-terminals and Core Residies of the Melanocyte- Stimulating Hormone on Binding to the Human Melanocortin Receptor Subtypes” Eur. J. Pharm, 1998, 349, 359-366. |
Al-Obeidi, et al., Journal of Medicinal Chemistry, vol. 35, No. 1, pp. 118-123, 1992. |